{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:29:53Z","timestamp":1790270993279,"version":"4.1.0"},"reference-count":139,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Culture and Innovation of Hungary","award":["TKP2021-EGA-18"],"award-info":[{"award-number":["TKP2021-EGA-18"]}]},{"name":"Ministry of Culture and Innovation of Hungary","award":["2022-1.2.2-T\u00c9T-IPARI-UZ-2022-00006"],"award-info":[{"award-number":["2022-1.2.2-T\u00c9T-IPARI-UZ-2022-00006"]}]},{"name":"TKP2021-EGA funding scheme","award":["TKP2021-EGA-18"],"award-info":[{"award-number":["TKP2021-EGA-18"]}]},{"name":"TKP2021-EGA funding scheme","award":["2022-1.2.2-T\u00c9T-IPARI-UZ-2022-00006"],"award-info":[{"award-number":["2022-1.2.2-T\u00c9T-IPARI-UZ-2022-00006"]}]},{"name":"Gedeon Richter Excellence PhD Scholarship of Gedeon Richter","award":["TKP2021-EGA-18"],"award-info":[{"award-number":["TKP2021-EGA-18"]}]},{"name":"Gedeon Richter Excellence PhD Scholarship of Gedeon Richter","award":["2022-1.2.2-T\u00c9T-IPARI-UZ-2022-00006"],"award-info":[{"award-number":["2022-1.2.2-T\u00c9T-IPARI-UZ-2022-00006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Psoriasis is a chronic inflammatory skin disease characterised by increased oxidative stress, the overproliferation of keratinocytes, the accumulation of inflammatory mediators, and skin barrier damage. Although a number of therapeutic options are available, finding long-term treatments that are well-tolerated and patient-friendly treatments remains a challenge. Tapinarof is a new type of aryl hydrocarbon receptor (AhR) modulator that has recently attracted attention as a promising non-steroidal alternative. However, its application may be limited by its poor water solubility and low degree of skin penetration. Nanotechnology-based drug carriers, specially nanogels, offer new opportunities to overcome these limitations by combining the advantages of targeted drug delivery and enhanced skin penetration. Furthermore, nanogel formulations can improve skin hydration and support the restoration of skin barrier function, which are important in the treatment of psoriasis. This review focuses on current and emerging therapeutic approaches, with particular emphasis on the potential of incorporating tapinarof into nanogel formulations as a novel alternative to topical psoriasis treatment.<\/jats:p>","DOI":"10.3390\/pharmaceutics17060731","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:27:09Z","timestamp":1748867229000},"page":"731","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tapinarof Nanogels as a Promising Therapeutic Approach"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0696-7805","authenticated-orcid":false,"given":"Barbara","family":"Balogh","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Utca 1, H-4002 Debrecen, Hungary"},{"name":"Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei K\u00f6r\u00fat 98, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-5708","authenticated-orcid":false,"given":"\u00c1gota","family":"Pet\u0151","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Utca 1, H-4002 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1lma","family":"Feh\u00e9r","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Utca 1, H-4002 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9724-0614","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Ujhelyi","sequence":"additional","affiliation":[{"name":"Department of Industrial Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Utca 1, H-4002 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2890","authenticated-orcid":false,"given":"Ildik\u00f3","family":"B\u00e1cskay","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Utca 1, H-4002 Debrecen, Hungary"},{"name":"Institute of Healthcare Industry, University of Debrecen, Rex Ferenc Utca 1, H-4002 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Madawi, E.A., Al Jayoush, A.R., Rawas-Qalaji, M., Thu, H.E., Khan, S., Sohail, M., Mahmood, A., and Hussain, Z. (2023). Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020657"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"104548","DOI":"10.1016\/j.jddst.2023.104548","article-title":"Breakthroughs and Bottlenecks of Psoriasis Therapy: Emerging Trends and Advances in Lipid Based Nano-Drug Delivery Platforms for Dermal and Transdermal Drug Delivery","volume":"84","author":"Singh","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Siafaka, P.I., \u00d6zcan B\u00fclb\u00fcl, E., Okur, M.E., Karantas, I.D., and \u00dcst\u00fcnda\u011f Okur, N. (2023). The Application of Nanogels as Efficient Drug Delivery Platforms for Dermal\/Transdermal Delivery. Gels, 9.","DOI":"10.3390\/gels9090753"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.prerep.2024.100004","article-title":"Treatment of Chronic Plaque Psoriasis: An Overview on Current Update","volume":"2","author":"Jurel","year":"2024","journal-title":"Pharmacol. Res.-Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1208\/s12249-021-02057-z","article-title":"Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis","volume":"22","author":"Biswasroy","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Makuch, S., Dr\u00f3\u017cd\u017c, M., Makarec, A., Zi\u00f3\u0142kowski, P., and Wo\u017aniak, M. (2022). An Update on Photodynamic Therapy of Psoriasis\u2014Current Strategies and Nanotechnology as a Future Perspective. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179845"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Dai, P., Ge, X., Sun, C., Jiang, H., Zuo, W., Wu, P., Liu, C., Deng, S., Yang, J., and Dai, J. (2023). A Novel Methacryloyl Chitosan Hydrogel Microneedles Patch with Sustainable Drug Release Property for Effective Treatment of Psoriasis. Macromol. Biosci., 23.","DOI":"10.1002\/mabi.202300194"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bodn\u00e1r, K., Feh\u00e9r, P., Ujhelyi, Z., B\u00e1cskay, I., and J\u00f3zsa, L. (2024). Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16040449"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.5114\/ada.2021.108445","article-title":"Treatments in Psoriasis: From Standard Pharmacotherapyto Nanotechnology Therapy","volume":"39","author":"Zhu","year":"2022","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"122991","DOI":"10.1016\/j.lfs.2024.122991","article-title":"Advances in Psoriasis Research: From Pathogenesis to Therapeutics","volume":"355","author":"Sugumaran","year":"2024","journal-title":"Life Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/1346-8138.17423","article-title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety Results from 2 Japanese Phase 3 Trials","volume":"51","author":"Igarashi","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Carmona-Rocha, E., Rusi\u00f1ol, L., and Puig, L. (2024). New and Emerging Oral\/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics, 16.","DOI":"10.20944\/preprints202401.0800.v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2023.12.013","article-title":"Tapinarof Validates the Aryl Hydrocarbon Receptor as a Therapeutic Target: A Clinical Review","volume":"154","author":"Silverberg","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1248\/bpbreports.7.4_116","article-title":"Pharmacological Properties of Tapinarof in Mice as a Novel Topical Agent for Plaque Psoriasis","volume":"7","author":"Urashima","year":"2024","journal-title":"BPB Rep."},{"key":"ref_15","first-page":"125325","article-title":"Transcutaneous Delivery of Disease Specific PI3K\/Akt\/mTOR Inhibitor Based Hybrid Nanoparticles in Hydrogel System for the Management of Psoriasis: Insights from in Vivo Studies","volume":"627","author":"Saha","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e15931","DOI":"10.1111\/dth.15931","article-title":"Tapinarof for the Treatment of Psoriasis","volume":"35","author":"Nogueira","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2022.05.012","article-title":"Nanocarriers for the Topical Treatment of Psoriasis\u2014Pathophysiology, Conventional Treatments, Nanotechnology, Regulatory and Toxicology","volume":"176","author":"Carvalho","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ahmad, M.Z., Mohammed, A.A., Algahtani, M.S., Mishra, A., and Ahmad, J. (2022). Nanoscale Topical Pharmacotherapy in Management of Psoriasis: Contemporary Research and Scope. J. Funct. Biomater., 14.","DOI":"10.3390\/jfb14010019"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yadav, T., Yadav, H., Raizaday, A., and Alam, M.S. (2024). The Treatment of Psoriasis via Herbal Formulation and Nanopolyherbal Formulation: A New Approach. BioImpacts, 15.","DOI":"10.34172\/bi.30341"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/PTT.S327310","article-title":"Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes Are More Than Innocent Bystanders","volume":"12","author":"Choudhary","year":"2022","journal-title":"Psoriasis Targets Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The Immunology of Psoriasis\u2014Current Concepts in Pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40257-021-00649-w","article-title":"New Topical Therapies for Psoriasis","volume":"23","author":"Torres","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"112630","DOI":"10.1016\/j.eurpolymj.2023.112630","article-title":"Advances in Hydrogels Based Cutaneous Drug Delivery System for Management of Psoriasis","volume":"202","author":"Vasowala","year":"2024","journal-title":"Eur. Polym. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"122938","DOI":"10.1016\/j.ijpharm.2023.122938","article-title":"An Overview of Topical Lipid-Based and Polymer-Based Nanocarriers for Treatment of Psoriasis","volume":"638","author":"Kaur","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"122535","DOI":"10.1016\/j.ijpharm.2022.122535","article-title":"Nanotechnology-Based Alternatives for the Topical Delivery of Immunosuppressive Agents in Psoriasis","volume":"631","author":"Gomes","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the Treatment of Psoriasis: A Review of the Unique Mechanism of Action of a Novel Therapeutic Aryl Hydrocarbon Receptor\u2013Modulating Agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/0976500X221130851","article-title":"Tapinarof: A Felicitous Discovery in Psoriasis Treatment","volume":"13","author":"Prabath","year":"2022","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.jaad.2021.01.056","article-title":"Tapinarof and the Future of Topical Treatments in Plaque Psoriasis","volume":"84","author":"Assaf","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/12034754241239050","article-title":"The Role of Aryl Hydrocarbon Receptor in the Pathogenesis and Treatment of Psoriasis","volume":"28","author":"Lin","year":"2024","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Shen, Q., Liu, R., Tan, S., Xu, X., Fang, J., and Li, R. (2022). Advances in Pathogenesis and Nanoparticles (NPs)-Mediated Treatment of Psoriasis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1089262"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lee, H.-J., and Kim, M. (2023). Challenges and Future Trends in the Treatment of Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713313"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/exd.14149","article-title":"How Can Nanoparticle-based Technologies Revolutionize the Topical Therapy in Psoriasis?","volume":"29","author":"Sindrilaru","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/10600280231164775","article-title":"A Review of Topical Tapinarof for the Treatment of Plaque Psoriasis","volume":"58","author":"Grossmann","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/87551225231193057","article-title":"Noncorticosteroid Topical Therapies for the Treatment of Plaque Psoriasis: A Narrative Review","volume":"39","author":"Chandy","year":"2023","journal-title":"J. Pharm. Technol."},{"key":"ref_35","first-page":"llae502","article-title":"Itching for Innovation: The Role of Aryl Hydrocarbon Receptor Agonists as a Future Therapy for Atopic Dermatitis","volume":"50","author":"Wazir","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2023.01.010","article-title":"Benvitimod Inhibits MCM6-Meditated Proliferation of Keratinocytes by Regulating the JAK\/STAT3 Pathway","volume":"109","author":"Cai","year":"2023","journal-title":"J. Dermatol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"29080","DOI":"10.1039\/D1RA06087B","article-title":"Lipid-Based Nanoparticles for Psoriasis Treatment: A Review on Conventional Treatments, Recent Works, and Future Prospects","volume":"11","author":"Ahmad","year":"2021","journal-title":"RSC Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: Treatment Targets for Plaque Psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","article-title":"A Phase 2, Randomized Dose-Finding Study of Tapinarof (GSK2894512 Cream) for the Treatment of Atopic Dermatitis","volume":"80","author":"Peppers","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Pareek, A., Kumari, L., Pareek, A., Chaudhary, S., Ratan, Y., Janmeda, P., Chuturgoon, S., and Chuturgoon, A. (2024). Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives. Cells, 13.","DOI":"10.3390\/cells13050425"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13671-019-0248-y","article-title":"Nanotechnology for Psoriasis Therapy","volume":"8","author":"Murphy","year":"2019","journal-title":"Curr. Dermatol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Petit, R.G., Cano, A., Ortiz, A., Espina, M., Prat, J., Mu\u00f1oz, M., Severino, P., Souto, E.B., Garc\u00eda, M.L., and Pujol, M. (2021). Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094983"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.6061\/clinics\/2021\/e3015","article-title":"Immunogenicity to Biological Drugs in Psoriasis and Psoriatic Arthritis","volume":"76","author":"Valenzuela","year":"2021","journal-title":"Clinics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s13555-023-00910-6","article-title":"Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA","volume":"13","author":"Fitzgerald","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2133531","DOI":"10.1080\/09546634.2022.2133531","article-title":"Guselkumab, Tildrakizumab, and Risankizumab in a Real-World Setting: Drug Survival and Effectiveness in the Treatment of Psoriasis and Psoriatic Arthritis","volume":"34","author":"Elgaard","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"106642","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib Is an Allosteric TYK2 Protein Kinase Inhibitor FDA-Approved for the Treatment of Psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_48","unstructured":"Ahsan, S., Degener, R., and Schlamp, M. (2025, March 09). Non-Invasive Treatments Invade the Psoriasis Pipeline. Available online: https:\/\/www.aquestconsulting.com\/wp-content\/uploads\/2023\/11\/Aquest_Non-Invasive-Psoriasis-Pipeline-White-Paper-FINAL-1123.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bang, C.-H., Park, C.-J., and Kim, Y.-S. (2025). The Expanding Therapeutic Potential of Deucravacitinib Beyond Psoriasis: A Narrative Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051745"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/10600280231153863","article-title":"Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis","volume":"58","author":"Truong","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40257-024-00897-6","article-title":"Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort Study","volume":"26","author":"Nissen","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2464107","DOI":"10.1080\/09546634.2025.2464107","article-title":"Oral Roflumilast for Psoriasis: A Real-World 24-Week Prospective Cohort Study","volume":"36","author":"Yilmaz","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5530\/jyp.20251506","article-title":"Systematizing PDE4 Inhibition in Psoriasis Treatment: Roflumilast Leads the Way","volume":"17","author":"Ravindran","year":"2025","journal-title":"J. Young Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40261-024-01368-w","article-title":"Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"44","author":"Mesquita","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"ref_55","first-page":"S1","article-title":"Tapinarof Cream 1% Once Daily for the Treatment of Adults with Mild to Severe Plaque Psoriasis: A Novel Topical Therapy Targeting the Aryl Hydrocarbon Receptor","volume":"29","author":"Armstrong","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2358150","DOI":"10.1080\/09546634.2024.2358150","article-title":"Effectiveness and Safety of Risankizumab in VEry Severe Plaque Psoriasis: A Real-Life Retrospective Study (VESPA-Study)","volume":"35","author":"Orsini","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s13555-024-01238-5","article-title":"Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials","volume":"14","author":"Gordon","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/12034754221078203","article-title":"Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers","volume":"26","author":"Vender","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40259-020-00416-z","article-title":"Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis","volume":"34","author":"Lee","year":"2020","journal-title":"BioDrugs"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Coto-Segura, P., Seg\u00fa-Verg\u00e9s, C., Martorell, A., Moreno-Ram\u00edrez, D., Jorba, G., Junet, V., Guerri, F., Daura, X., Oliva, B., and Cara, C. (2023). A Quantitative Systems Pharmacology Model for Certolizumab Pegol Treatment in Moderate-to-Severe Psoriasis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1212981"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e14929","DOI":"10.1111\/dth.14929","article-title":"Certolizumab Pegol in the Treatment of Psoriasis: Real-life Data","volume":"34","author":"Turkmen","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/jdds.jdds_66_23","article-title":"Tildrakizumab in Psoriasis and Beyond","volume":"28","author":"Bubna","year":"2024","journal-title":"J. Dermatol. Dermatol. Surg."},{"key":"ref_63","unstructured":"Bagel, J. (2025, April 02). Biologics in Psoriasis: The Next Generation. Practical Dermatology. Available online: https:\/\/practicaldermatology.com\/topics\/psoriasis\/biologics-in-psoriasis-the-next-generation\/20807\/."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2147\/CCID.S464326","article-title":"Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study","volume":"17","author":"Megna","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2024.03.025","article-title":"Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis of the Scalp: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3b Study","volume":"91","author":"Gebauer","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40267-021-00840-3","article-title":"Guselkumab in Psoriatic Arthritis: A Profile of Its Use","volume":"37","author":"Lamb","year":"2021","journal-title":"Drugs Ther. Perspect."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II\/III Clinical Studies in Psoriasis and Psoriatic Arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Megna, M., Ruggiero, A., Martora, F., Vallone, Y., Guerrasio, G., and Potestio, L. (2024). Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13092691"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100287","DOI":"10.1016\/j.xjidi.2024.100287","article-title":"Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy","volume":"4","author":"Blauvelt","year":"2024","journal-title":"JID Innov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1358\/dot.2017.53.5.2613690","article-title":"Brodalumab: The First Anti-IL-17 Receptor Agent for Psoriasis","volume":"53","author":"Puig","year":"2017","journal-title":"Drugs Today"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s13555-024-01264-3","article-title":"Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses","volume":"14","author":"Lebwohl","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s13555-022-00746-6","article-title":"Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis","volume":"12","author":"Menter","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40257-017-0254-4","article-title":"Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis","volume":"18","author":"Syed","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2160196","DOI":"10.1080\/09546634.2022.2160196","article-title":"Real-World Evidence for Ixekizumab in the Treatment of Psoriasis and Psoriatic Arthritis: Literature Review 2016\u20132021","volume":"34","author":"Reich","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.2147\/JIR.S229752","article-title":"Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection","volume":"14","author":"Miller","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_76","unstructured":"(2025, March 09). PubChem Tapinarof, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6439522."},{"key":"ref_77","unstructured":"(2025, March 09). Benvitimod \u2265 98% (HPLC)|Sigma-Aldrich. Available online: https:\/\/www.sigmaaldrich.com\/HU\/en\/product\/sigma\/sml3430."},{"key":"ref_78","unstructured":"(2025, March 09). Tapinarof|99.98%(HPLC)|AhR Agonist. Available online: https:\/\/www.selleckchem.com\/products\/tapinarof.html."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Pecyna, P., Wargula, J., Murias, M., and Kucinska, M. (2020). More Than Resveratrol: New Insights into Stilbene-Based Compounds. Biomolecules, 10.","DOI":"10.3390\/biom10081111"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof Is a Natural AhR Agonist That Resolves Skin Inflammation in Mice and Humans","volume":"137","author":"Smith","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.freeradbiomed.2024.07.032","article-title":"Tapinarof and Its Structure-Activity Relationship for Redox Chemistry and Phototoxicity on Human Skin Keratinocytes","volume":"223","author":"Zatloukalova","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"ref_82","first-page":"136","article-title":"Treatment Challenges in Atopic Dermatitis with Novel Topical Therapies","volume":"7","author":"Shah","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.10.037","article-title":"Phase 2, Randomized Dose-Finding Study of Tapinarof (GSK2894512 Cream) for the Treatment of Plaque Psoriasis","volume":"80","author":"Robbins","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hu, Y.-Q., Liu, P., Mu, Z., and Zhang, J.-Z. (2022). Anti-Inflammatory Effects of AhR Agonist Benvitimod in TNF\u03b1\/IFN\u03b3 Stimulated HaCaT Cells and Peripheral Blood Mononuclear Cells from Patients with Atopic Dermatitis. arXiv.","DOI":"10.21203\/rs.3.rs-1699070\/v1"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.jaad.2021.10.053","article-title":"A Novel Topical Treatment for Plaque Psoriasis: Benvitimod\/Tapinarof","volume":"86","author":"Zhang","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-022-01748-6","article-title":"Tapinarof Cream 1%: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"114122","DOI":"10.1016\/j.ejmech.2022.114122","article-title":"Identification of Triazolopyridine Derivatives as a New Class of AhR Agonists and Evaluation of Anti-Psoriasis Effect in a Mouse Model","volume":"231","author":"Tian","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jdv.18925","article-title":"Tapinarof for Psoriasis and Atopic Dermatitis: 15 Years of Clinical Research","volume":"37","author":"Bissonnette","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ali, S., Ion, A., Orzan, O.A., and B\u0103l\u0103ceanu-Gur\u0103u, B. (2024). Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16111425"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14656566.2021.2016699","article-title":"An Overview of Benvitimod for the Treatment of Psoriasis: A Narrative Review","volume":"23","author":"Lu","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-Year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results from the PSOARING 3 Trial","volume":"87","author":"Strober","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","article-title":"Efficacy and Patient-Reported Outcomes from a Phase 2b, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Adolescents and Adults with Atopic Dermatitis","volume":"84","author":"Paller","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Santini, G., Bonati, L., and Motta, S. (2025). From Tapinarof to Novel AhR Modulators: Computational Drug Discovery for Psoriasis Therapeutics. Res. Sq., Preprint posted.","DOI":"10.21203\/rs.3.rs-6063129\/v1"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0065-2164(08)70479-9","article-title":"Insect Microbiology","volume":"Volume 1","author":"Umbreit","year":"1959","journal-title":"Advances in Applied Microbiology"},{"key":"ref_95","unstructured":"(2025, March 09). An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% in Subjects With Atopic Dermatitis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05142774."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1097\/CM9.0000000000003260","article-title":"Tapinarof Inhibits Psoriatic Inflammation through Inducing Tolerogenic Dendritic Cells and Foxp3+ Tregs","volume":"137","author":"Zhao","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e14862","DOI":"10.1111\/exd.14862","article-title":"The Opposite Effect of Tapinarof between IMQ and IL-23 Induced Psoriasis Mouse Models","volume":"33","author":"Zhu","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40257-021-00641-4","article-title":"Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics","volume":"23","author":"Jett","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_99","unstructured":"(2025, March 09). A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05172726."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1346-8138.17587","article-title":"A Phase 2, Randomized, Double-blind, Vehicle-controlled Trial of Tapinarof Cream in Japanese Pediatric Patients with Atopic Dermatitis","volume":"52","author":"Igarashi","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13555-024-01318-6","article-title":"Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children","volume":"15","author":"Simpson","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_102","unstructured":"(2025, March 09). A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05032859."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","article-title":"Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials","volume":"91","author":"Silverberg","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e70041","DOI":"10.1111\/srt.70041","article-title":"A Comparison of the Safety and Efficacy of Tapinarof and Roflumilast Topical Therapies in the Management of Mild-to-moderate Plaque Psoriasis","volume":"30","author":"Ghani","year":"2024","journal-title":"Skin Res. Technol."},{"key":"ref_105","unstructured":"Teva Pharmaceuticals USA (2024). A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site, Clinical Study to Evaluate the Therapeutic Equivalence of Tapinarof Cream 1% (Teva Pharmaceuticals, Inc.) with VTAMA\u00ae Tapinarof (Tapinarof) Cream 1% (Dermavant Sciences, Inc.) in Adult Patients with Plaque Psoriasis."},{"key":"ref_106","unstructured":"(2025, March 09). A Phase 4, Open-Label, Study to Investigate the Efficacy and Safety of VTAMA\u00ae (Tapinarof) Cream 1% in the Treatment of Plaque Psoriasis in Intertriginous Areas, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05680740."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1208\/s12249-018-0997-0","article-title":"Biodegradable Ingredient-Based Emulgel Loaded with Ketoprofen Nanoparticles","volume":"19","author":"Gul","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1515\/ntrev-2021-0115","article-title":"Approved and Marketed Nanoparticles for Disease Targeting and Applications in COVID-19","volume":"10","author":"Abdellatif","year":"2021","journal-title":"Nanotechnol. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Yin, Y., Hu, B., Yuan, X., Cai, L., Gao, H., and Yang, Q. (2020). Nanogel: A Versatile Nano-Delivery System for Biomedical Applications. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030290"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Mastella, P., Todaro, B., and Luin, S. (2024). Nanogels: Recent Advances in Synthesis and Biomedical Applications. Nanomaterials, 14.","DOI":"10.20944\/preprints202407.0821.v1"},{"key":"ref_111","first-page":"09673911231192816","article-title":"Review on Nanogels and Their Applications on Dermal Therapy","volume":"31","author":"Botha","year":"2023","journal-title":"Polym. Polym. Compos."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Gupta, V., Mohapatra, S., Mishra, H., Farooq, U., Kumar, K., Ansari, M., Aldawsari, M., Alalaiwe, A., Mirza, M., and Iqbal, Z. (2022). Nanotechnology in Cosmetics and Cosmeceuticals\u2014A Review of Latest Advancements. Gels, 8.","DOI":"10.3390\/gels8030173"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Fytianos, G., Rahdar, A., and Kyzas, G.Z. (2020). Nanomaterials in Cosmetics: Recent Updates. Nanomaterials, 10.","DOI":"10.3390\/nano10050979"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"103176","DOI":"10.1016\/j.jddst.2022.103176","article-title":"Lipid Nanoparticles in Topical Dermal Drug Delivery: Does Chemistry of Lipid Persuade Skin Penetration?","volume":"69","author":"Ghouse","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/2230-973X.133053","article-title":"Enhanced Transdermal Permeability of Piroxicam through Novel Nanoemulgel Formulation","volume":"4","author":"Aggarwal","year":"2014","journal-title":"Int. J. Pharm. Investig."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Algahtani, M.S., Ahmad, M.Z., Nourein, I.H., Albarqi, H.A., Alyami, H.S., Alyami, M.H., Alqahtani, A.A., Alasiri, A., Algahtani, T.S., and Mohammed, A.A. (2021). Preparation and Characterization of Curcumin Nanoemulgel Utilizing Ultrasonication Technique for Wound Healing: In Vitro, Ex Vivo, and In Vivo Evaluation. Gels, 7.","DOI":"10.3390\/gels7040213"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Li, N., Qin, Y., Dai, D., Wang, P., Shi, M., Gao, J., Yang, J., Xiao, W., Song, P., and Xu, R. (2022). Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis. Front. Bioeng. Biotechnol., 9.","DOI":"10.3389\/fbioe.2021.804415"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/08982104.2019.1593449","article-title":"Preparation, Characterization, and in Vivo Evaluation of Cyclosporine Cationic Liposomes for the Treatment of Psoriasis","volume":"30","author":"Walunj","year":"2020","journal-title":"J. Liposome Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2147\/IJN.S156412","article-title":"Pivotal Role of Acitretin Nanovesicular Gel for Effective Treatment of Psoriasis: Ex Vivo&ndash;in Vivo Evaluation Study","volume":"13","author":"Hamed","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_120","first-page":"876","article-title":"Nano-Transferosomes of Aloe-Vera and Vitamin-E for Management of Psoriasis: An Archetype in Herbal Drug Technology","volume":"9","author":"Vohra","year":"2023","journal-title":"Int. J. Innov. Res. Technol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1208\/s12249-023-02678-6","article-title":"Quality-by-Design Approach for Investigating the Efficacy of Tacrolimus and Hyaluronic Acid\u2013Loaded Ethosomal Gel in Dermal Management of Psoriasis: In Vitro, Ex Vivo, and In Vivo Evaluation","volume":"24","author":"Dadwal","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Serini, S., Trombino, S., Cassano, R., Marino, M., and Calviello, G. (2025). Anti-Inflammatory Effects of Curcumin-Based Nanoparticles Containing \u03b1-Linolenic Acid in a Model of Psoriasis In Vitro. Nutrients, 17.","DOI":"10.3390\/nu17040692"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Llorente, X., Esteruelas, G., Bonilla, L., Agudelo, M.G., Filgaira, I., Lopez-Ramajo, D., Gong, R.C., Soler, C., Espina, M., and Garc\u00eda, M.L. (2023). Riluzole-Loaded Nanostructured Lipid Carriers for Hyperproliferative Skin Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098053"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"18340","DOI":"10.1021\/acsomega.3c00924","article-title":"Evolving Trends in Nanofibers for Topical Delivery of Therapeutics in Skin Disorders","volume":"8","author":"Tomar","year":"2023","journal-title":"ACS Omega"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.biomaterials.2018.08.030","article-title":"Curcumin-Loaded Lipid-Hybridized Cellulose Nanofiber Film Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice","volume":"182","author":"Kang","year":"2018","journal-title":"Biomaterials"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"43588","DOI":"10.1021\/acsami.9b15668","article-title":"Hyaluronic Acid-Based Dissolving Microneedle Patch Loaded with Methotrexate for Improved Treatment of Psoriasis","volume":"11","author":"Du","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1007\/s12668-024-01373-5","article-title":"A Review on Nanosystem-Based Delivery of Tofacitinib for Enhanced Treatment of Autoimmune Diseases and Inflammation","volume":"14","author":"Nguyen","year":"2024","journal-title":"BioNanoScience"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Manimaran, V., Nivetha, R.P., Tamilanban, T., Narayanan, J., Vetriselvan, S., Fuloria, N.K., Chinni, S.V., Sekar, M., Fuloria, S., and Wong, L.S. (2023). Nanogels as Novel Drug Nanocarriers for CNS Drug Delivery. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1232109"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4155\/tde-2019-0010","article-title":"Nanogels As Drug-Delivery Systems: A Comprehensive Overview","volume":"10","author":"Suhail","year":"2019","journal-title":"Ther. Deliv."},{"key":"ref_130","first-page":"WC04","article-title":"Tretinoin Nanogel 0.025% Versus Conventional Gel 0.025% in Patients with Acne Vulgaris: A Randomized, Active Controlled, Multicentre, Parallel Group, Phase IV Clinical Trial","volume":"9","author":"Chandrashekhar","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3109\/10837450.2015.1026605","article-title":"A Novel Nanogel Formulation of Methotrexate for Topical Treatment of Psoriasis: Optimization, in Vitro and in Vivo Evaluation","volume":"21","author":"Avasatthi","year":"2016","journal-title":"Pharm. Dev. Technol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"124172","DOI":"10.1016\/j.ijpharm.2024.124172","article-title":"Formulation Development of Nanostructured Lipid Carrier-Based Nanogels Encapsulating Tacrolimus for Sustained Therapy of Psoriasis","volume":"660","author":"Kakade","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1039\/D4BM00224E","article-title":"Recent Advances in Nanogels for Drug Delivery and Biomedical Applications","volume":"12","author":"Vashist","year":"2024","journal-title":"Biomater. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1568026622666220818112728","article-title":"Nanogel-Based Transdermal Drug Delivery System: A Therapeutic Strategywith Under Discussed Potential","volume":"23","author":"Tariq","year":"2023","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_135","unstructured":"Kraus, J.E., and Lee, J. (2025, May 19). Use of Tapinarof for the Treatment of Chronic Plaque Psoriasis. Available online: https:\/\/patents.google.com\/patent\/US11590088B2\/en."},{"key":"ref_136","unstructured":"Kraus, J.E., and Lee, J. (2025, May 19). Use of Tapinarof for the Treatment of Atopic Dermatitis. Available online: https:\/\/patents.google.com\/patent\/US11938099B2\/en?oq=US11938099B2."},{"key":"ref_137","unstructured":"Arkin, M., and Zighelboim, M. (2025, May 19). Treatment of Ocular Diseases with Ophthalmic Tapinarof Compositions. Available online: https:\/\/patents.google.com\/patent\/US20210000758A1\/en?oq=US20210000758A1."},{"key":"ref_138","unstructured":"Jain, P., Tabolt, G., Rubenstein, D.S., Kalluri, H., Catubig, R., Roughan, B., Buchta, R., Bonjour, F.M.G., Brady, B.P., and Sutcliffe, L.H. (2025). Gel, Ointment, and Foam Formulations of Tapinarof and Methods of Use 2022. (Application 17\/533,885), U.S. Patent."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Balogh, B., Pet\u0151, \u00c1., Haimhoffer, \u00c1., Sinka, D., K\u00f3sa, D., Feh\u00e9r, P., Ujhelyi, Z., Argenziano, M., Cavalli, R., and B\u00e1cskay, I. (2024). Formulation and Evaluation of Different Nanogels of Tapinarof for Treatment of Psoriasis. Gels, 10.","DOI":"10.3390\/gels10110675"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/6\/731\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:45:42Z","timestamp":1760031942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/6\/731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":139,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["pharmaceutics17060731"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17060731","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}